Previous 10 | Next 10 |
home / stock / prvcf / prvcf news
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of two of its patent families. The patent family...
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent ...
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intellig...
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A...
Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria, KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844H PreveCeutical's Pain Man...
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (C...
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent famil...
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective F...
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organiza...
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds a...
News, Short Squeeze, Breakout and More Instantly...
PreveCeutical Medical Inc Company Name:
PRVCF Stock Symbol:
OTCMKTS Market:
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") is providing an update with respect to the Management Cease Trade Order (" MCTO ") issued by the British Columbia Securities Com...
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financ...
2023-12-04 10:00:34 ET %Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue-targeted b...